Checked content

Huntington's disease

Related subjects: Health and medicine

Did you know...

SOS Children volunteers helped choose articles and made other curriculum material SOS Children has looked after children in Africa for forty years. Can you help their work in Africa?

Huntington's disease
Classification and external resources

George Huntington's 1872 paper described the disorder.
ICD- 10 G 10, F 02.2
ICD- 9 333.4, 294.1
OMIM 143100
DiseasesDB 6060
MeSH D006816

Huntington's disease, also called Huntington's chorea, chorea major, or HD, is a genetic neurological disorder characterized by abnormal body movements called chorea and a lack of coordination; it also affects a number of mental abilities and some aspects of behaviour. The name is derived from the physician George Huntington who described the disorder in 1872. In 1993 the gene causing HD was found, making it one of the first inherited genetic disorders for which an accurate test could be performed. Because of this, and the disorder having aspects applicable to other neurological disorders such as Alzheimer's disease, it has been extensively researched since then.

The gene causing the disorder is dominant and may, therefore, be inherited from a single parent. Global incidence varies, from 3 to 7 per 100,000 people of Western European descent, down to 1 per 1,000,000 of Asian and African descent. The onset of physical symptoms in Huntington's disease occur in a large range around a mean of a person's late forties to early fifties. If symptoms become noticeable before a person is the age of twenty, then their condition is known as Juvenile HD.

Huntington's disease is one of several polyglutamine diseases caused by a trinucleotide repeat expansion. This expansion is in the Huntingtin gene, which normally codes for Huntingtin protein (Htt), producing mutant Huntingtin (mHtt). The presence of this protein increases the rate of neuron cell death in select areas of the brain, affecting certain neurological functions. The loss of neurons isn't fatal, but complications caused by symptoms reduce life expectancy. There is currently no proven cure, so symptoms are managed with a range of medications and supportive services.


Symptoms increase in severity progressively, but aren't often recognised until they reach certain stages. Physical symptoms are usually the first to cause problems and be noticed, but these are accompanied by cognitive and psychiatric ones which aren't often recognized. Almost everyone with Huntington's Disease eventually exhibits all physical symptoms, but cognitive symptoms vary, and so any psychopathological problems caused by these, also vary per individual. The symptoms of juvenile HD differ in that they generally progress faster and are more likely to exhibit rigidity and bradykinesia instead of chorea and often include seizures.


The most characteristic symptoms are jerky, random, and uncontrollable movements called chorea, although sometimes very slow movement and stiffness ( bradykinesia, dystonia) can occur instead or in later stages. These abnormal movements are initially exhibited as general lack of coordination, an unsteady gait and slurring of speech. As the disease progresses, any function that requires muscle control is affected, this causes reduced physical stability, abnormal facial expression, impaired speech comprehensibility, and difficulties chewing and swallowing. Eating difficulties commonly cause weight loss. HD has been associated with sleep cycle disturbances, including insomnia and rapid eye movement sleep alterations.

Counter intuitively, there may be some health benefits as carriers of the gene are hypothesized to have higher levels of the tumor suppressor protein p53 and a better than average immune system than non-carriers. As of April 2008, neither of these hypotheses have been supported by rigorous study.


Selective cognitive abilities are progressively impaired, including executive function (planning, cognitive flexibility, abstract thinking, rule acquisition, initiating appropriate actions and inhibiting inappropriate actions), psychomotor function (slowing of thought processes to control muscles), perceptual and spatial skills of self and surrounding environment, selection of correct methods of remembering information (but not actual memory itself), short-term memory, and ability to learn new skills, depending on the pathology of the individual.


Psychopathological symptoms vary more than cognitive and physical ones, and may include anxiety, depression, a reduced display of emotions ( blunted affect) and decreased ability to recognize negative expressions like anger, disgust, fear or sadness in others, egocentrism, aggression, and compulsive behaviour. The latter can cause, or worsen, hypersexuality and addictions such as alcoholism and gambling.


The gene involved in Huntington's disease, called Huntingtin (Htt), or Interesting Transcript 15 (IT15) gene, known historically as the HD gene, is located on the short arm of chromosome 4 (4p16.3). In the first part, called the 5' end of the gene, is a sequence of three DNA bases— cytosine- adenine- guanine (CAG)— repeated multiple times (i.e. ...CAGCAGCAG...) and known as a trinucleotide repeat. CAG is the genetic code for the amino acid glutamine; thus a series of CAG forms a chain of glutamine known as polyglutamine (polyQ).

Effect classification repeat count
unaffected normal < 27
intermediate 27 - 35
affected Reduced Penetrance 36 - 39
Full Penetrance > 39

A polyQ length of less than 36 glutamines produces a cytoplasmic protein called huntingtin protein (Htt), whereas a sequence of 36 or more produces an erroneous form of Htt, mHtt (standing for mutant Htt), this causes certain neurons, in select areas of the brain, to have an increased mortality. As the number of neurons reduces in these areas their functionality is impaired. Generally, the number of CAG repeats is related to the rate that these neurons die, affecting the age at onset and progression of symptoms. Counts of 36-39 repeats result in later onset and slower progression of symptoms termed "reduced penetrance". No case of HD has been diagnosed with a count of less than 36.


HD is inherited in an autosomal dominant fashion.

Huntington's disease is autosomal dominant, needing only one affected allele from either parent to inherit the disease. Although this generally means there is a one in two chance of inheriting the disorder from an affected parent, the inheritance of HD is more complex due to potential dynamic mutations, where DNA replication doesn't produce an exact copy of itself. This can cause the number of repeats to change in successive generations. This can mean that a parent with a count close to the threshold, may pass on a gene with a count either side of the threshold. Repeat counts maternally inherited are usually similar, whereas paternally inherited ones tend to increase. This potential increase in repeats in successive generations is known as anticipation.

In families where neither parent has HD, new mutations account for truly sporadic cases of the disease. The frequency of these de novo mutations is extremely low.,

Homozygous individuals, who carry two mutated genes because both parents passed on one, are rare. While HD seemed to be the first disease for which homozygotes did not differ in clinical expression or course from typical heterozygotes, more recent analysis suggest that homozygosity affects the phenotype and the rate of disease progression though it does not alter the age of onset suggesting that the mechanisms underlying the onset and the progression are different.


Like all proteins, Htt and mHtt are translated, perform or affect biological functioning, and are finally dissolved in a process called biodegradation. The exact role mHtt has in DNA replication and its influence in programmed cell death is unknown. Research focuses on identifying the functioning of Htt, how mHtt differs or interferes with it, and the proteopathy of remnants of mHtt, left after biodegradation.


The Htt protein is involved in vesicle trafficking as it interacts with HIT1, a clathrin binding protein, to mediate endocytosis, the absorption of materials into a cell.

The mHtt protein reduces the production of brain-derived neurotrophic factor (BDNF). BDNF protects neurons and regulates the neurogenesis of new ones. The precise way it does this is unknown but a reduction in its level increases neuron cell death and creation, leading to atrophy of areas of the brain.


Both Htt and mHtt are cleaved (the first step in degradation) by caspase-3, which removes the protein's amino end (the N-terminal). Caspase-2 then further breaks down the amino terminal fragment (the part with the CAG repeat) of Htt, but cannot process all of the mHtt protein. The unprocessed pieces left in the cell are called aggregates, or N-fragments, and are able to affect genetic transcription. Specifically, mHtt binds with TAFII130, a coactivator to CREB dependent transcription. The aggregates also interact with the transcription factor protein SP1, preventing it from binding to DNA.

In transgenic mice neurodegeneration caused by mHtt is related to the caspase-6 enzyme cleaving the Htt protein, as they did not show effects of HD in experiments.

In genetically altered "knockin" mice, the extended CAG repeat portion of the gene is all that is needed to cause disease. Aggregates of mHtt are present in the brains of people and mice with HD, and are most prevalent in cortical pyramidal neurons, less so in striatal medium-sized spiny neurons and almost absent in most other brain regions including the hippocampus and cerebellum. These aggregates consist mainly of the amino terminal end of mHtt (CAG repeat), and are found in both the cytoplasm and nucleus of neurons. The presence of these aggregates however does not correlate with cell death. Thus mHtt acts in the nucleus but does not cause apoptosis through aggregation.



Studies on physiopathology are mainly focused on the brain since most symptoms are caused by its altered functioning.

Profound neuronal degeneration in the striatum with some additional atrophy of the frontal and temporal cortices. There is also astrogliosis and loss of medium spiny neurons.

The brain initiates motion by sending a signal down the spinal cord from the external globus pallidus. At the same time that the stimulus is being sent down the spinal cord, the subthalamic nuclei of the striatum excite the internal globus pallidus, which inhibits the thalamus and modulates motion.

In Huntington's disease the external globus pallidus over-inhibits the flow of excitation from the subthalamic nuclei, which interferes with the initiation of motion. The subthalamic nuclei also generate reduced excitation to the internal globus pallidus, resulting in a weak inhibitory signal to the thalamus. The thalamus in turn then sends a strong excitatory signal to the putamen resulting in unmodulated motion.

Other systems

Huntington's disease appears to affect non nervous physiological functions. One study in humans highlighted a systemic, early hypermetabolic state and a lower level of branched chain amino acids in the plasma as the disease progresses; this seems to originate from the brain's own need for energetic substrates.

In a murine model, heart restricted expression of amyloid-forming polyglutamine fragments resulted in heart failure.


To determine whether initial symptoms are evident, a physical and/or psychological examination is required. The uncontrollable movements are often the symptoms which cause initial alarm and lead to diagnosis; however, the disease may begin with cognitive or emotional symptoms, which are not always recognized. Pre-symptomatic testing is possible by means of a blood test which counts the number of repetitions in the gene.

A negative blood test means that the individual does not carry the expanded copy of the gene, will never develop symptoms, and cannot pass it on to children. A positive blood test means that the individual does carry the expanded copy of the gene, will develop the disease, and has a 50% chance of passing it on to children. A pre-symptomatic positive blood test is not considered a diagnosis, because it may be decades before onset.

Because of the ramifications on the life of an at-risk individual, with no cure for the disease and no proven way of slowing it, several counseling sessions are usually required before the blood test. Unless a child shows significant symptoms or is sexually active or considered to be Gillick competent, children under eighteen will not be tested. The members of the Huntington's Disease Society of America strongly encourage these restrictions in their testing protocol. A pre-symptomatic test is a life-changing event and a very personal decision. Embryonic screening is also possible, giving HD carriers or at-risk individuals the option of ensuring their children will not inherit the disease if abortion is acceptable to them. It is possible to test an embryo either in the womb ( prenatal diagnosis) or to ensure a child will not have HD by utilising in vitro fertilisation and testing before implantation.

A full pathological diagnosis can only be established by a neurological examination's findings and/or demonstration of cell loss in the areas affected by HD, supported by a cranial CT or MRI scan findings.


There is no treatment to fully arrest the progression of the disease, but symptoms can be reduced or alleviated through the use of medication and care methods. Huntington mice models exposed to better husbandry techniques, especially better access to food and water, lived much longer than mice that were not well cared for.


Other standard treatments to alleviate emotional symptoms include the use of antidepressants and sedatives, with antipsychotics (in low doses) for psychotic symptoms.


Speech therapy helps by improving speech and swallowing methods; this therapy is more effective if started early on, as the ability to learn is reduced as the disease progresses. A two-year pilot study, of intensive speech, pyschiatric and physical therapy, applied to inpatient rehabilitation, showed motor decline was greatly reduced.


Nutrition is an important part of treatment; most third and fourth stage HD sufferers need two to three times the calories of the average person to maintain body weight. Healthier foods in pre-symptomatic and earlier stages may slow down the onset and progression of the disease. High calorie intake in pre-symptomatic and earlier stages has been shown to speed up the onset and reduce IQ level.

Thickening agent can be added to drinks as swallowing becomes more difficult, as thicker fluids are easier and safer to swallow. The option of using a stomach PEG is available when eating becomes too hazardous or uncomfortable; this greatly reduces the chances of aspiration of food, and the subsequent increased risk of pneumonia, and increases the amount of nutrients and calories that can be ingested.

EPA, an Omega-3 fatty acid, may slow and possibly reverse the progression of the disease. As of April 2008, it is in FDA clinical trial as ethyl-EPA, (brand name Miraxion), for prescription use. Clinical trials utilise 2 grams per day of EPA. In the United States, it is available over the counter in lower concentrations in Omega-3 and fish oil supplements. Results of the first Phase III trial showed an improvement in motor function scores over the control group, but a larger trial is required before these results can be considered conclusive.


Development of Huntington’s disease is highly dependent on how many times CAG is repeated. Usually, CAG is repeated between 7 and 35 times; more than this, however, will cause the disease. The age of onset (and to a degree the severity of the disease), and hence the age at death, are inversely correlated with the length of the expanded CAG repeat, such that those with longer repeats develop the disease earlier. Individuals with greater than approximately 60 CAG repeats often develop juvenile Huntington's disease. There is a large variation in age of onset for any given CAG repeat length within the intermediate range (40-50 CAGs). For example, a repeat length of 40 CAGs leads to an onset ranging from 40 to 70 years of age in the North American and Canadian population. This variation means that, although logarithmic algorithms have been proposed for predicting the age of onset, in reality predicting the precise age of onset can be generalised, but not precisely predicted with confidence.

Following the onset of obvious physical diagnosis of the disorder, life expectancy is generally a further 15 to 20 years. Mortality is not caused by Huntington’s disease directly, but by associated complications, these include pneumonia (which causes one third of fatalities), heart failure (although heart disease, cerebrovascular disease and atherosclerosis show no increase), choking and nutritional deficiencies. Suicide is an associated risk, with suicide rates of up to 7.3 percent; four times that of the general population. Suicide, in general, is likely to be underestimated; reports, which have accounted for this, estimate up to 27 percent of possibly affected individuals attempt suicide.

Social impact

Whether or not to have the test for HD Genetic counseling may provide perspective for those at risk of the disease. Some choose not to undergo HD testing due to numerous concerns (for example, insurability). Testing of a descendant of a person, who is 'at-risk', has serious ethical implications as a positive result automatically diagnoses one of the parents.

Parents and grandparents have to decide when and how to tell their children and grandchildren. The issue of disclosure also comes up when siblings are diagnosed with the disease, and especially in the case of identical twins.

For those at risk, or known to have the disease, consideration is necessary prior to having children due to the genetically dominant nature of the disease. In vitro and embryonic genetic screening make it possible to ensure the gene is not passed on with high accuracy.

Huntington's disease was one of the targets of the eugenics movement, for example the American scientist Charles Davenport proposed in 1910 that compulsory sterilization and immigration control be used for people with certain disease, including HD.

Financial institutions are also faced with the question of whether to use genetic testing results when assessing an individual, e.g. for life insurance. Some countries' organisations have already agreed not to use this information.


As HD is autosomal dominant, and does not usually affect reproduction, areas of increased prevalence occur according to historical migration of carriers, some of which can be traced back thousands of years using the genes haplotypes. New mutations are less than 10 percent of HD carriers, but account for the less localised occurrences, and origins, of the disorder.

Since the discovery of a genetic test that can also be used pre-symptomatically, estimates of the incidence of the disorder are likely to increase. This is because, without the genetic test, only individuals displaying physical symptoms and a few neurologically examined cases were diagnosed, which excluded anyone who died of other causes before diagnosis. These cases can now be included in statistics as the test becomes more widely available.

The prevalence is, on average, between 3 to 7 per 100,000 people of Western European descent, down to 1 per 1,000,000 of Asian and African descent, but this varies greatly according to geographical location, both by ethnicity and local migration. The highest occurrence is in peoples of Western Europe descent, and relatively lower in the rest of the world. For example the isolated populations of the Lake Maracaibo region of Venezuela ( where the marker for the gene was discovered ), have an extremely high prevalence of up to 700 per 100,000, leading to the conclusion that one of their initial founders must have been a carrier of the gene. This is known as the local founder effect.

About 7 percent of HD cases occur in people under the age of 20 years. This is referred to as Juvenile HD, "akinetic-rigid", or "Westphal variant" HD.


In the first part of the twentieth century and earlier, many people with HD were misdiagnosed as suffering from alcoholism or manic depression. Previously mortality due to starvation or dehydration was a major risk.

  • c. 300: Along with other conditions with abnormal movements, it may have been referred to as St Vitus' dance. St Vitus is the patron saint of epileptics who was martyred in 303.
  • Middle Ages: People with the condition were probably persecuted as being witches or as being possessed by spirits, and were shunned, exiled or worse. Some speculate that the "witches" in the Salem Witch Trials in 1692 had HD.
  • 1860: One of the early medical descriptions of HD was made in 1860 by a Norwegian district physician, Johan Christian Lund. He noted that in Setesdalen, a remote and rather secluded area, there was a high prevalence of dementia associated with a pattern of jerking movement disorders that tended to run in families. This is the reason for the disease being commonly referred to as Setesdalsrykkja (Setesdalen=the location, rykkja=jerking movements) in Norwegian.
  • 1872: George Huntington was the third generation of a family medical practice in Long Island. With their combined experience of several generations of a family with the same symptoms, he realised their conditions were linked and set about describing it. A year after leaving medical school, in 1872, he presented his accurate definition of the disease to a medical society in Middleport, Ohio.
  • c. 1923: Smith Ely Jelliffe (1866–1945) and Frederick Tilney (1875–1938) began analyzing the history of HD sufferers in New England.
  • 1932: P. R. Vessie expanded Jelliffe and Tilney's work, tracing about a thousand people with HD back to two brothers and their families who left Bures in Essex for Suffolk bound for Boston in 1630.
  • 1979: The U.S-Venezuela Huntington's Disease Collaborative Research Project began an extensive study which gave the basis for the gene to be discovered. This was conducted in the small and isolated Venezuelan fishing villages of Barranquitas and Lagunetas. Families there have a high presence of the disease.
  • 1983: James Gusella, David Housman, P. Michael Conneally, Nancy Wexler, and their colleagues find the general location of the gene, using DNA marking methods for the first time — an important first step toward the Human Genome Project.
  • 1992: Anita Harding, et al., find that trinucleotide repeats affect disease severity
  • 1993: The Huntington's Disease Collaborative Research Group isolates the precise gene at 4p16.3.
  • 1996: A transgenic mouse ( the R6 line) was created that could be made to exhibit HD, greatly advancing how much experimentation can be achieved.
  • 1997: DiFiglia M, Sapp E, Chase KO, et al., discover that mHtt aggregates ( misfolds) to form nuclear inclusions.
  • The full record of research is extensive.

Society and culture

As public awareness has increased, HD has been depicted increasingly in numerous books, films and TV series. Early works were Arlo Guthrie's 1969 film Alice's Restaurant and Jacqueline Susann's 1966 American novel Valley of the Dolls , with more recent references in ER, Private Practice, Everwood, All Saints, and House. As of 2008, June 6th is designated "National Huntington's Disease Awareness Day" by the USA senate, and the UK HDA holds an awareness week the third week of June.


  • 1967: Woody Guthrie's wife, Marjorie, helped found the Committee to Combat Huntington's Disease, after his death from HD complications. This eventually became the Huntington's Disease Society of America. Since then, lay organizations have been formed in many countries around the world.
  • 1968: After experiencing HD in his wife's family Dr. Milton Wexler was inspired to start the Hereditary Disease Foundation (HDF). Professor Nancy S. Wexler, Dr. Wexler's daughter, was in the research team in Venezuela and is now president of the HDF.
  • 1974: The first international meeting took place when the founders of the Canadian HD Society (Ralph Walker) and of the British HD Society (Mauveen Jones) attended the annual meeting of the American HD Society.
  • 1977: second meeting organized by the Dutch Huntington Society the "Vereniging van Huntington", representatives of six countries were present.
  • 1979: International Huntington Association (IHA) formed during international meeting in Oxford, England organized by HDA of England.
  • 1981–2001: Biennial meetings held by IHA which became the World Congress on HD.
  • 2003: The first World Congress on Huntington's Disease was held in Toronto. This is a biennial meeting for associations and researchers to share ideas and research, which is held on odd-number years. The Euro-HD Network was started as part of the Huntington Project, funded by the High-Q Foundation.

Research directions

Appropriate animal models are critical for understanding the fundamental mechanisms causing the disease and for supporting the early steps of drug development before moving on to human clinical trials. Neurochemically induced mice or monkeys were first available , but they could not mimick the progressive features of the disease. After the HD gene was discovered, transgenic animals exhibiting HD were generated by inserting a CAG repeat expansion into the genome of mice (strain R6/2 ), Drosophila fruit flies, or more recently in monkeys. Expression without insertion of a CAG repeat in nematode worms also produced a valuable model.

As for humans, there are trials of various compounds that are in development, recruiting volunteers, in progress or completed. Some of these trials are at the point of testing on larger numbers of people, known as phase III of the clinical trials.

Intrabody therapy

Genetically engineered antibody fragments called intrabodies have shown therapeutic results against mHtt aggregates in drosophila models. This was achieved using an intrabody called C4 sFv, a single chain variable fragment which binds to the end of mHtt within a cell. C4 sFv has been shown to reduce mHtt aggregate formation and accumulation in cultures of tissue taken from the model. The intrabody increased larval and pupal survival from 23% to 100% and delayed neurodegeneration in the adult, significantly increasing their lifespan. Intrabody therapy shows promise as a tool for drug discovery, and as a potential therapy for neurodegenerative disorders caused by protein mis-folding or abnormal protein interactions.

Gene silencing

Since HD has been conclusively linked to a single gene, gene silencing could be simpler than with multiple-gene disorders. Researchers have investigated using gene knockdown of mHtt as a potential treatment. Using a mouse model, siRNA therapy achieved a 60 percent reduction in expression of the mHtt and progression of the disease was stalled. However, this study used the human form of the Htt gene in the mouse, and were therefore able to directly target the mHtt gene, leaving endogenous, wild-type Htt gene expression unaffected. Since no single nucleotide polymorphisms have yet been discovered in mHtt it would be impossible, using siRNA, to distinguish between wild-type and mutant forms of the gene. The precise function of Htt is unknown, but the htt knockout mutation is lethal and kills mice during emryogenesis. Thus, using RNA interference to knockout both wild-type and mutant htt could have unforeseen, unfavourable consequences. Other issues associated with siRNA therapy are delivering the gene, off-target effects of siRNA, and toxicity from shRNA over-expression.

In another study, mouse models in late stages of the disease recovered motor function after expression of mHtt was shut down.

Stem cell implants

Treatment using stem cell implants is based on the replacement of damaged neurons by injecting stem cells, which can form themselves into specialized cells, into the damaged area. The stem cell then transforms itself into a replacement neuron. If enough damaged neurons are replaced, symptoms should be alleviated. This treatment would not prevent further neuronal damage, so would be an ongoing treatment. The treatment has yielded some positive results in animal models.


Other agents and measures that have shown promise in initial experiments include dopamine receptor blockers, select dopamine antagonists, such as tetrabenazine, creatine, CoQ10, the antibiotic Minocycline, antioxidant-containing foods and nutrients, and antidepressants, including selective serotonin reuptake inhibitors ( SSRIs) such as sertraline, fluoxetine, and paroxetine.

Retrieved from ""